The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Cystic Fibrosis (CF) Therapeutics Market Projected To Reach By 2030?
The size of the cystic fibrosis (cf) therapeutics market has experienced strong growth in recent years. Its value is projected to rise from $8.34 billion in 2025 to $8.91 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.8%. This historical expansion can be attributed to the high prevalence of cystic fibrosis, limited early diagnostic tools, reliance on conventional mucolytic therapies, the gradual adoption of cftr modulators, and variations in regional healthcare infrastructure.
The cystic fibrosis (cf) therapeutics market is projected to experience robust expansion over the coming years, with its size anticipated to reach $11.72 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This expected growth during the forecast period is primarily driven by advancements in gene therapy, the increasing adoption of digital health solutions, the expansion of precision medicine applications, the growth of pediatric cf treatment programs, and heightened investment in rare disease therapeutics. Notable trends foreseen in this period include the development of personalized cystic fibrosis therapies, sophisticated pulmonary drug delivery systems, intensive research into gene editing and CFTR gene therapy, innovative patient adherence and remote monitoring solutions, and the focus on orphan drug development for rare cf mutations.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9056&type=smp
What Key Factors Are Shaping The Cystic Fibrosis (CF) Therapeutics Market Landscape?
The projected expansion of the cystic fibrosis (CF) therapeutics market is anticipated due to a rising number of individuals affected by cystic fibrosis. Cystic fibrosis (CF) refers to a genetic disorder significantly impairing the lungs, digestive system, and various other organs of the body. Therapeutics for cystic fibrosis are employed to manage this condition, primarily by thinning the mucus in the lungs to facilitate easier expectoration. Consequently, a greater prevalence of cystic fibrosis patients is set to invigorate the cystic fibrosis (CF) therapeutics market. For example, data from the Cystic Fibrosis Foundation, a U.S.-based nonprofit, non-governmental organization (NGO), indicated that the CF Patient Registry grew by approximately 2.3% from 32,547 individuals in 2022 to 33,288 in 2023. Hence, the expanding patient base with cystic fibrosis is a key factor propelling the expansion of the cystic fibrosis (CF) therapeutics market.
Which Segment Types Are Examined In The Cystic Fibrosis (CF) Therapeutics Market Segment Study?
The cystic fibrosis (cf) therapeutics market covered in this report is segmented –
1) By Drug Class: Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, CFTR Modulators
2) By Route Of Administration: Oral, Inhaled
3) By Treatment Method: Medication, Devices
Subsegments:
1) By Pancreatic Enzyme Supplements: Lipase, Amylase, Protease
2) By Mucolytics: Dornase Alfa (Pulmozyme), Hypertonic Saline
3) By Bronchodilators: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Anticholinergics
4) By CFTR Modulators: Ivacaftor, Lumacaftor Or Ivacaftor (Orkambi), Tezacaftor Or Ivacaftor (Symdeko), Elexacaftor Or Tezacaftor Or Ivacaftor
What Market Trends Are Affecting The Cystic Fibrosis (CF) Therapeutics Market?
Leading companies in the cystic fibrosis (CF) therapeutics market are driving innovation in treatment and patient care solutions, such as through the creation of cystic fibrosis innovation hub networks. These efforts are geared towards accelerating research, improving treatment options, and fostering enhanced collaboration in developing new therapies for CF patients. The cystic fibrosis innovation hub network operates as a cooperative platform or initiative specifically designed to expedite the research and development of novel treatments for cystic fibrosis (CF). For instance, in October 2024, LifeArc, a UK-based charity and life sciences company focused on translating scientific research into actionable healthcare solutions, launched the first Cystic Fibrosis Innovation Hub Network in the UK. This Cystic Fibrosis Innovation Hub Network is intended to bolster research and development for cystic fibrosis (CF) treatments, promoting partnerships among healthcare providers, researchers, and patients. Initiated as part of a broader strategy to accelerate innovation in cystic fibrosis therapies, the hub concentrates on identifying new methods for drug development and enhancing patient outcomes.
Which Players Are Part Of The Competitive Landscape Of The Cystic Fibrosis (CF) Therapeutics Market?
Major companies operating in the cystic fibrosis (cf) therapeutics market are Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestlé HealthScience, Pharmaxis, Bayer AG, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd. , Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals , Translate Bio Inc, Zambon S.p.A
Get The Full Cystic Fibrosis (CF) Therapeutics Market Report:
Which Region Holds The Highest Market Share In The Cystic Fibrosis (CF) Therapeutics Market?
North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (cf) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cystic Fibrosis (CF) Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cystic Fibrosis (CF) Therapeutics Market 2026, By The Business Research Company
Cystic Fibrosis Cf Therapeutics Market Report 2026
Non Cystic Fibrosis Bronchiectasis Market Report 2026
Idiopathic Pulmonary Fibrosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model